Healthcare / Medical - PharmaceuticalsUpdated 2026-05-10 22:07 UTC

LON/0HL9 stock hub

LON/0HL9 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LON/0HL9is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

3.6K

London Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

LON/0HL9

In the news

Latest news · LON/0HL9

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.9P50 16.9P75 23.5

Trailing P/En/a

P25 15.9P50 22.9P75 35.8

ROE-149.5

P25 -54.2P50 2.1P75 13.7

ROIC-62.1

P25 -38.1P50 3.3P75 11.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LON/0HL9 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

166

Groups with data

Currency

EUR

Showing 166 of 166 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	Netherlands
Country code	UK
Employees	76
Employees Change	-143%
Employees Change Percent	-65.3
Enterprise value	$-9.2M
Exchange	London Stock Exchange
Financial currency	EUR
First seen	2026-05-10
Industry	Medical - Pharmaceuticals
Isin	NL0015001ZQ0
Last refreshed	2026-05-10
Market cap	$3,609
Price	$0
Price currency	USD
Rev Per Employee	61,720.97x
Sector	Healthcare
Sic	2836
Symbol	lon/0HL9
Website	https://www.affimed.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-1,613,231.15%
EV Earnings	0.16x
EV/FCF	0.14x
FCF yield	-1,785,413.69%
P/B ratio	0x
P/S ratio	0x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Gross Profit	$4.7M
Gross Profit Growth	-72.92%
Gross Profit Growth Q	-91.62%
Gross Profit Growth3 Y	-48.32%
Gross Profit Growth5 Y	-32.61%
Net Income	$-58.2M
Net Income Growth Quarters	4%
Pretax Margin	-1,241.19%
Profit Per Employee	$-766,120
ROA	-49.42
Roa5y	-24.39
ROCE	-273.6
ROE	-149.5
Roe5y	-74.47
ROIC	-62.15

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-99.98%
Cagr3y	-97.16%
Cagr5y	-92.8%
EPS Growth Quarters	4
Revenue Growth	-72.92x
Revenue Growth Q	-91.62x
Revenue Growth3 Y	-48.32x
Revenue Growth5 Y	-32.61x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.07
Assets	$33.3M
Cash	$20.1M
Current Assets	$28M
Current Liabilities	$14.5M
Debt	$10.7M
Debt Equity	$0.75
Debt FCF	$-0.17
Equity	$14.3M
Interest Coverage	-46.74
Liabilities	$18.9M
Long Term Assets	$5.2M
Long Term Liabilities	$4.4M
Net Cash	$9.3M
Net Cash By Market Cap	$258,481
Net Cash Growth	-85.33%
Net Debt Equity	$-0.65
Tangible Book Value	$14.3M
Tangible Book Value Per Share	$0.87
WACC	8.32

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.93
Net Working Capital	$-1.3M
Quick ratio	1.71
Working Capital	$13M
Working Capital Turnover	$0.1

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-3.15%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-99.98%
200-day SMA	0.19
3Y total return	-100%
50-day SMA	0
50-day SMA vs 200-day SMA	50under200
5Y total return	-100%
All Time High	115.6
All Time High Change	-100%
All Time High Date	2021-04-28
All Time Low	0
All Time Low Change	19,900%
All Time Low Date	2026-03-16
ATR	0
Beta	0.31
Ch YTD	100
High	0
High52	0.86
High52 Date	2025-05-06
High52ch	-99.98%
Low	0
Low52	0
Low52 Date	2026-04-28
Low52ch	19,900%
Ma50ch	100%
Price vs 200-day SMA	-99.89%
RSI	54.1
RSI Monthly	30.1
RSI Weekly	26.18
Sharpe ratio	1.78x
Sortino ratio	158.3
Total Return	-3.15%
Tr YTD	100
Tr1m	100%
Tr1w	100%
Tr3m	100%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$-52.8M
Operating margin	-1,125.2

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Net Borrowing	-5,716,129.4
Shares Qo Q	5.22%
Short Ratio	23.34

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-67.4M
Average Volume	469.45x
Bv Per Share	0.87
CAPEX	$-444,365
Ch1m	100
Ch1w	100
Ch1y	-99.98
Ch3m	100
Ch3y	-100
Ch5y	-100
Ch6m	100
Change	0%
Change From Open	0
Depreciation Amortization	2,310,499.6
Dollar Volume	0.33
Earnings Date	2026-06-01
EBIT	$-52.8M
EBITDA	$-50.6M
EPS	$-3.78
F Score	1
FCF	$-64.4M
FCF EV Yield	702.51x
Financing CF	594,151
Fiscal Year End	December
Founded	2,000
Income Tax	$3,329
Investing CF	16,375,755
Is Primary Listing	0
Last Earnings Date	2025-08-08
Last Report Date	2024-09-30
Last Split Date	2024-03-11
Last Split Type	Reverse
Ma150	0.01
Ma150ch	-98.44%
Ma20	0
Ma20ch	100%
Net CF	-46,110,744
Next Earnings Date	2026-06-01
Open	0
Ppne	6,533,584.3
Price Date	2026-05-06
Ptbv Ratio	0
Relative Volume	3.48x
Revenue	4,690,794x
SBC By Revenue	64.02x
Share Based Comp	3,003,206
Tax By Revenue	0.07x
Tr6m	100%
Volume	1,633
Z Score	-23.33

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does LON/0HL9 pay a dividend?

Capital-return profile for this ticker.

Performance

LON/0HL9 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Technical

LON/0HL9 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

54.1

Neutral momentum band

Price vs 200-day MA

-99.9%

50/200-day relationship not available

Beta (5Y)

0.31

Less volatile than the market

Sharpe ratio

1.78

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LON/0HL9

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/0HL9 stock rating?

lon/0HL9 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/0HL9 analysis?

The full report lives at /stocks/lon/0HL9/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/0HL9?

The latest report frames lon/0HL9 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/0HL9 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.